icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Evaluation of Factors Associated With Differences in ALT Normalization
Between Virally Suppressed TAF- and TDF-Treated CHB Patients

 
 
    Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
 
Harry L. Janssen,1 Shalimar,2 Chi-Yi Chen,3 Owen Tak Yin Tsang,4 Jenny C. Yang,5 Hongyuan Wang,5 Anuj Gaggar,5 John F. Flaherty,5 Mani Subramanian,5 Huy N. Trinh,6 Florin A. Caruntu,7 Maria Buti,8 Scott Fung1
1Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 2All India Institute of Medical Sciences, New Delhi, India; 3Chia-Yi Christian Hospital, Chiayi City, Taiwan; 4Princess Margaret Hospital, Hong Kong;
5Gilead Sciences, Inc., Foster City, CA; 6Silicon Valley Research Institute, San Jose, CA; 7National Institute for Infectious Diseases "Prof. Dr. Matei Bals," Bucharest, Romania; 8Hospital Vall d'Hebron, Barcelona, Spain

1108171

1108172

1108173

1108174

1108175

1108176

References
 
1. Agarwal K, et al. EASL 2017, abstr 153; 2. Brunetto M, et al. EASL 2017, abstr PS-042;
3. Chan HL, et al. EASL 2017, abstr PS-041; 4. Fung S, et al. AASLD 2016, abstr 1852; 5. Terrault NA, et al. Hepatology 2016;63:261-83.